IPHA (Innate Pharma) Dividends per Share : $0.00 (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma Dividends per Share?

Innate Pharma's dividends per share for the six months ended in Dec. 2024 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2024 was 0.00. As of today, Innate Pharma's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Innate Pharma Dividends per Share Historical Data

The historical data trend for Innate Pharma's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Dividends per Share Chart

Innate Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

Innate Pharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Innate Pharma's Dividends per Share

For the Biotechnology subindustry, Innate Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Innate Pharma Dividends per Share Calculation

Dividends paid to per common share.

Innate Pharma (NAS:IPHA) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Innate Pharma's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.314
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Innate Pharma Dividends per Share Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

IPHYF:USA 0EVI:UK IPH:France

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.